Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus

Journal of the American College of Cardiology

Volumn 42, Issue 2, 2003, Pages 328-335

  Diamant, Michaela ^a,b   Lamb, Hildo J ^a   Groeneveld, Ymte ^a   Endert, Edwin L ^a   Smit, Jan W A ^a   Bax, Jeroen J ^a   Romijn, Johannes A ^a   De Roos, Albert ^a   Radder, Jasper K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLE; HEART DISEASE; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HIGH ENERGY PHOSPHATE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

EID: 0038488294     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00625-9     Document Type: Article

References (38)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year CVD mortality for men screened in the Multiple Risk Factor Intervention trial. Diabetes Care 1993;16:434-44.
2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
3. Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M. LV function and dimensions in newly diagnosed NIDDM. Am J Cardiol 1992;70:371-8.
4. Di Bonito P, Cuomo S, Moio N, et al. Diastolic dysfunction in patients with NIDDM of short duration. Diabet Med 1996;13:321-4.
5. Felicio JS, Ferreira SRG, Plavnik FL, et al. Effect of blood glucose on LV mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 2000;13:1149-54.
6. Sánchez-Barriga JJ, Rangel A, Castañeda R, et al. LV diastolic dysfunction secondary to hyperglycemia in patients with type 2 diabetes. Arch Med Res 2001;32:44-7.
7. Beljic T, Miric M. Improved metabolic control does not reverse LV filling abnormalities in newly diagnosed NIDDM patients. Acta Diabetol 1994;31:147-50.
8. Bell DSH. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease. Diabetes Care 1995;18:708-14.
9. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of the energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25-34.
10. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998;180:53-7.
11. Zhou YT, Grayburn P, Karim A, et al. Lipotoxlc heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-9.
12. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of FFA oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263-76.
13. Lamb HJ, Beyerbracht HP, Van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999;99:2261-7.
14. WHO Expert Committee on Diabetes Mellitus. Second report. WHO Tech Rep Ser 1980;646:1-80.
15. Ewing D, Clarke B. Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982;285:916.
16. Lamb HJ, Doornbos J, Vander Velde EA, Kruit MC, Reiber JH, De Roos A. Echo planar MRI of the heart on a standard system: validation of measurements of LV function and mass. J Comput Assist Tomogr 1996;20:942-9.
17. Hartiala JJ, Mostbeck GH, Foster E, et al. Velocity-encoded cine MRI in the evaluation of LV diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve. Am Heart J 1993;125:1054-66.
18. Pattynama PMT, Lamb HJ, Van der Velde EA, Van der Geest RJ, Van der Wall EE, De Roos A. LV measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology 1993;187:261-8.
19. 31P-NMR spectroscopy. NMR Biomed 1996;9:217-27.
20. 31P-MRS. Circulation 1997;96:2969-77.
21. Van der Veen JWC, de Beer R, Luyten PR, Van Ormondt D. Accurate quantification of in vivo 31-P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988;6:92-8.
22. De Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, Van der Wall EE, Den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 1992;2:711-9.
23. Bottomley PA, Hardy CJ, Weiss RG. Correcting human heart 31P-NMR spectra for partial saturation: evidence that saturation factors for PCr/ATP are homogeneous in normal and disease states. J Magn Reson 1991;95:341-55.
24. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
25. Missouris CG, Forbat SM, Singer DRJ, Markandu ND, Underwood R, MacGregor GA. Echocardiography overestimates LV mass: a comparative study with MRI in patients with hypertension. J Hypertens 1996;14:1005-10.
26. Poirier P, Garneau C, Bogaty P, et al. Impact of LV diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 DM. Am J Cardiol 2000;85:473-7.
27. Forman DE, Manning WJ, Hauser R, Gervino GV, Evans WJ, Wei JY. Enhanced LV diastolic filling associated with long-term endurance training. J Gerontol 1992;47:M56-8.
28. Hoffmann U, Globits S, Stefenelli T, Loewe C, Kostner K, Frank H. The effects of ACE inhibitor therapy on LV myocardial mass and diastolic filling in previously untreated hypertensive patients: a cine MRI study. J Magn Reson Imaging 2001;14:16-22.
29. Ingwall S, Kramer MF, Fifer MA, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985;313:1050-4.
30. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104-13.
31. Gross WL, Bak MI, Ingwall JS, et al. NO inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci USA 1996;93:5604-9.
32. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in NIDDM patients evaluated by FDG-PET. J Nucl Med 1995;36:456-63.
33. Utriainen T, Takala T, Luotolahti M, et al. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 1998;41:555-9.
34. Kuikka JT, Mustonen JN, Uusitupa MIJ, et al. Demonstration of disturbed FFA metabolism of myocardium in patients with NIDDM as measured with iodine-123-heptadecanoic acid. Eur J Nucl Med 1991;18:475-81.
35. Sakamoto K, Yamasaki Y, Nanto S, et al. Mechanism of impaired LV wall motion in the diabetic heart without coronary artery disease. Diabetes Care 1998;21:2123-8.
36. Knuuti J, Takala TO, Nagren K, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001;44:184-7.
37. Bakker SJL, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and β-cell failure? Atherosclerosis 2000;148:17-21.
38. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996;79:940-8.